FAIR VALUE MEASUREMENTS

9 Months Ended

Apr. 30, 2026

NOTE 5: FAIR VALUE MEASUREMENTS

The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of April 30, 2026 and July 31, 2025:

	Fair Value Measurements at
	April 30, 2026						July 31, 2025
	Level 1		Level 2		Total		Level 1		Level 2		Total
Financial Assets:
Cash and cash equivalents		6,880,221		-		6,880,221		10,493,808		-		10,493,808
Short-term investments		15,924,204		-		15,924,204		7,372,473		-		7,372,473
Total assets measured at fair value	$	22,804,425	$	-	$	22,804,425	$	17,866,281	$	-	$	17,866,281

Financial liabilities:
Warrants liability		-		71,854		71,854		151,586		186,086		337,672

Total liabilities measured at fair value	$	-	$	71,854	$	71,854	$	151,586	$	186,086	$	337,672

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

NOTE 5: FAIR VALUE MEASUREMENTS (Cont.)

The Company classifies cash and cash equivalents and the liability in respect of publicly traded warrants within Level 1 because we use quoted market prices in active markets.

As of April 30, 2026 and July 31, 2025, the Company held Level 1 short-term investments measured using quoted prices in active markets. As of April 30, 2026, the Company’s short-term investments had coupon rates ranging from 1.13% to 5.59%. As of July 31, 2025, the Company’s short-term investments had coupon rates ranging from 3.00% to 5.51%.

The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for the liability either directly or indirectly, and thus are classified as Level 2 financial instruments.